Skip to content
Life Sciences Series A Founded 2011

Pepticom

Developer of AI-based technology for the discovery of peptide drug candidates. The platform's technology is an algorithm that assists in protein-protein interface and peptide-protein interface enabling the design of binding peptides, agonists, and antagonists that are intended to block protein-protein interactions. It analyzes the target surface surrounding the desired binding area and then performs a design process…

📍 Jerusalem, Israel · Genomics,

Funding snapshot

Last roundSeries A
Amount$7M
Date7 January 2025
Total raised$8M
Team size16

About

Developer of AI-based technology for the discovery of peptide drug candidates. The platform's technology is an algorithm that assists in protein-protein interface and peptide-protein interface enabling the design of binding peptides, agonists, and antagonists that are intended to block protein-protein interactions. It analyzes the target surface surrounding the desired binding area and then performs a design process to provide a peptide library with optimal binding affinity. Founded in 2011, headquartered in Jerusalem, Israel. The company has raised $7.6M at the Series A stage backed by investors including Chartered High Tech, Chartered Group. Operating in Life Sciences > Genomics, HealthTech > Life Sciences Tech.

Business model

Life Sciences Tech > Research & Development > Drug Discovery > Proteomics,

Genomics > Applied Genomics > Clinical Genomics > Therapeutics

Institutional investors

Chartered High Tech Chartered Group

Latest coverage

No articles yet.

Raising like Pepticom?

Analyze your pitch deck before your next raise.

Analyze My Deck →